MAPT and tauopathy: The in silico ADME, admetSAR, and BBB results indicated that the top five lead molecules (Ligands 1–5) were the potential inhibitors and non-toxic attributes to clinical safety concerns of in p-tau therapeutics in AD and tauopathies models.